- Home
- MGTX vs ABSI Comparison
MGTX vs ABSI Comparison
Compare MGTX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$7.97
HOLD
Current Price
$3.57
Company Overview
Basic Information| Metric | MGTX | ABSI |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.7M | 577.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGTX | ABSI |
|---|---|---|
| Price | $7.97 | $3.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $23.83 | $7.98 |
| AVG Volume (30 Days) | 518.4K | ★ 3.9M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,417,000.00 | $2,815,000.00 |
| Revenue This Year | N/A | $10.72 |
| Revenue Next Year | $619.95 | $437.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.83 | N/A |
| 52 Week Low | $4.55 | $2.01 |
| 52 Week High | $9.73 | $6.33 |
Technical Indicators
Market Signals| Indicator | MGTX | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 53.17 |
| Support Level | $7.77 | $3.37 |
| Resistance Level | $8.40 | $3.79 |
| Average True Range (ATR) | 0.55 | 0.25 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 10.69 | 34.51 |
Price Performance
Historical Comparison MGTX
ABSI
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.